FindTrial
Sign In

The Efficacy and Safety of the new biologic agents (humanized anti-human Interlukin-6 receptor monoclonal antibody) on abnormal lipid metabolism and atherosclerosis for rheumatoid arthritis patients in Japan

The Efficacy and Safety of the new biologic agents (humanized anti-human Interlukin-6 receptor monoclonal antibody) on abnormal lipid metabolism and atherosclerosis for rheumatoid arthritis patients in Japan - The Efficacy and Safety of the new humanized anti-human interlukin-6 reCeptor mOnoclonal antibody on abnormal lipid metabolism and atherosclerosis for Rheumatoid arthritis in Japan (The ESCORT study)

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000001407
Enrollment
120
Registered
2008-10-01
Start date
2008-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Sponsors

The First Department of Internal Medicine.University of Occupation & Environmental Health
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed to have rheumatoid arthritis according to the criteria proposed by American College of Rheumatology in 1987 patients with rheumatoid arthritis of more than 6 months duration

Exclusion criteria

Exclusion criteria: RA patients who have serious infection patients who have history of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies patients with Primary or secondary immunodeficiency

Design outcomes

Primary

MeasureTime frame
Adiponectin Remnant like particles-cholesterol Each type of serum cholesterol Carotid echo sonography—

Secondary

MeasureTime frame
DAS28 Remission rate ACR core set Total Sharp Score—

Countries

Japan

Contacts

Public ContactKazuyoshi Saito

University of Occupation & Environmental Health The First Department of Internal Medicine

kazu-s@med.uoeh-u.ac.jp093-603-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026